First-line treatment patterns and overall survival in patients diagnosed with metastatic Merkel cell carcinoma in England from 2013 to 2020: results of a nationwide observational cohort study

Br J Dermatol. 2025 May 19;192(6):1134-1136. doi: 10.1093/bjd/ljaf063.

Authors

Seyed Hamidreza Mahmoudpour¹, Craig Knott², Jenny Nobes³, Mairead Kearney⁴, Emmanuelle Boutmy¹, Patrice Verpillat¹, Zoe C Venables^{5

6}

Affiliations

¹ Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.
² Health Data Insight CIC, NHS England, London, UK.
³ Department of Oncology, Norfolk and Norwich University Hospital, Norwich, UK.
⁴ Global Value Demonstration, Market Access and Pricing, Merck Healthcare KGaA, Darmstadt, Germany.
⁵ Department of Dermatology, Norfolk and Norwich University Hospital, Norwich, UK.
⁶ Norwich Medical School, University of East Anglia, Norwich, UK.

PMID: 40036636
DOI: 10.1093/bjd/ljaf063

No abstract available

Grants and funding

Merck